Our Research

Discover our recent findings, catch up with news, and review in-depth resources and case studies.

Connect with Resolian at these upcoming events.

Advancing Immunoassay Method Development and Automation at Resolian

Precision, efficiency, and scientific expertise are essential in today’s fast-moving bioanalytical landscape. At Resolian, we’ve taken a bold step forward—restructuring teams, refining method development processes, and strategically implementing automation to enhance service delivery.
Read more

De-risk Your Drug Development with Resolian’s Polymorph Screening Expertise

Polymorph screening is a process that identifies and characterizes the crystalline forms of a compound, and then selects the best form for development. Assessing and controlling the crystalline form of your material plays a crucial role in all the stages of the product lifecycle.
Read more

Foreign Particulate Matter Solutions for Vaccine Safety

Foreign particulate matter (FPM) in vaccines poses risks to product safety, patient health, and regulatory compliance. With stringent guidelines from agencies like the FDA and EMA, identifying and controlling contaminants is essential to maintaining trust and ensuring safety.
Read more

Oligonucleotide Therapeutics Podcast

Min Meng, Chief Operations Officer at Resolian. The interview focuses on the bioanalysis of oligonucleotide therapeutics, a rapidly evolving area in drug development. Min Meng, with 20+ years of experience in this field, provides valuable insights into the unique challenges and advantages of these therapies.
Read more
Sustainability in Extractables and Leachables.

Sustainability in Extractables and Leachables

Resolian is committed to reducing its environmental impact wherever feasibly possible. Recently the Extractables and Leachables team at the Fordham lab of Analytical Sciences aimed to implement and evaluate green chemistry principles.
Read more

Australian Clinical Trials Podcast

In this visual podcast we explore why Australia is an attractive destination for early-phase clinical trials, highlighting the benefits of speed, quality, and cost-effectiveness. The expert panel discussion delves into Australia’s unique regulatory pathways, the R&D tax incentives, operational logistics, and how early-phase data supports global drug development.
Read more
Scroll to Top

Harmonizing Quality Standards Across Global Labs with David Butler

In a globalized life sciences industry, maintaining consistent quality standards across multiple international sites is a major challenge. For Resolian, a bioanalytical CRO with labs on four continents, the harmonization of processes is essential to delivering reliable, high-quality results for clients, regardless of location.

Resolian has taken a strategic approach to developing standard operating procedures (SOPs), a focus on informed compliance, and a strong commitment to building a unified global team.

In this episode, David Butler, Vice President Corporate Quality, discusses the steps involved in in harmonizing a global bsuiness and Resolian’s aims to deliver a more impactful, tailored, service for Resolian’s clients.

Watch the video below

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.